Rivastigmine in current clinical practice in patients with mild to moderate alzheimer's disease;Utilisation de la rivastigmine en pratique médicale courante chez des patients ambulatoires présentant une maladie d'alzheimer

Revue Neurologique

Volumn 158, Issue 8-9, 2002, Pages 807-812

  Dartigues, J F ^a   Goulley, F ^a   Bourdeix, I ^a   Pere J J ^a   Barberger Gateau, P ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; RIVASTIGMINE;

ABDOMINAL DISEASE; AGED; AGITATION; ALZHEIMER DISEASE; ANXIETY DISORDER; APATHY; ARTICLE; ASTHENIA; CLINICAL PRACTICE; CLINICAL TRIAL; CONFUSION; CORRELATION ANALYSIS; DAILY LIFE ACTIVITY; DELUSION; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DRUG EFFECT; DRUG SAFETY; FEMALE; FRANCE; HEADACHE; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; MALAISE; MALE; MINI MENTAL STATE EXAMINATION; NAUSEA; PHASE 4 CLINICAL TRIAL; PSYCHOLOGIC ASSESSMENT; SOMNOLENCE; SYNCOPE; VOMITING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CARBAMATES; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DRUG TOLERANCE; ENGLISH ABSTRACT; FEMALE; HUMAN; MALE; MIDDLE AGE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 0036756311     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. American Psychiatric Association. (1994). Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC, American Psychiatric Association, 142-143.
2. Barberger-Gateau P, Dartigues JF, Letenneur L. (1993). Four instrumental activities of daily living score as a predictor of one-year incident dementia. Age and Ageing, 22: 457-463.
3. Brodaty H. (1999). Realistic expectations for the management of Alzheimer's disease. European Neuropsychopharm, 9: 43-52.
4. Corey-Bloom J, Anand R, Veach J for the ENA 713 B352 Study Group. (1998). A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinestherase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int Geriatr Psychopharmacol, 1: 55-65.
5. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. (1994). The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology, 44: 2308-2314.
6. Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, Drachman DA, et al. (1992). A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med, 327: 1253-1259.
7. Enz A, Boddeke H, Gray J, Spiegle R. (1991). Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor. Ann New York Acad Sci, 640: 272-275.
8. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowski CH, Dolan-Ureno J. (1992). A controlled trial of tacrine in Alzheimer's disease. JAMA, 268: 2523-2529.
9. Folstein MR, Folstein SE, McHugh PR. (1975). "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res, 12: 189-198.
10. Lawton MP, Brody EM. (1969). Assessment of older people: Self maintaining and Instrumental Activities of Daily Living. Gerontologist, 9: 179-186.
11. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. (1984). Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34: 939-944.
12. Mittelman MS, Ferris SH, Shulman E, Steinberg G, Levin B. (1996). A family intervention to delay nursing home placement of patients with Alzheimer's disease. A randomized controlled trial. JAMA, 276: 1725-1731.
13. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal Bianco P, Stahelin HB, et al. (1999). Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomized controlled trial. BMJ, 318: 633-638.